Recruiting
Early Phase 1

Dapsone & Standard Treatment

Sponsor:

Hunt Regional Medical Center

Code:

NCT04918914

Conditions

SARS-CoV-2

Hypoxia

ARDS

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Dapsone 100 MG

Study Details

Brief summary:

Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3).

Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor.

Methods:

Patients who were on standard COVID-19 therapy are also after obtaining off label uses and explanation of side effects are started on dapsone 100-200 mg daily along with Cimetadine 400 mg three times daily.

Conditions

SARS-CoV-2

Hypoxia

ARDS

Study ID

NCT04918914

Start date

Oct 18, 2020

Status verified date

Jun, 2021

Completion date

Dec 31, 2021

Anticipated

Primary completion date

Dec 31, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. All, PCR confirmed cases of COVID-19

Exclusion Criteria:

1. Only consenting consenting patients

-

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Intervention

Interventions

Dapsone 100 MG

Dapsone 100-200 md orally daily, along with Cimetadine 400 mg PO TID

Primary outcome measure

  • Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Kanwar

4694228931bkanwar2@yahoo.com

Locations

Hunt Regional Medical Center

Recruiting

Greenville, Texas, United States, 75401

Contacts

Badar Kanwar

469-422-8931BKANWAR2@YAHOO.COM

More Information

Sponsor

Hunt Regional Medical Center

Last update posted

Jun 9, 2021

Last verified

Jun, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Hunt Regional Medical Center on 2021-06-09.